文献速递骨肿瘤创伤骨科

原发性骨肿瘤全肱骨置换的假体生存率与功能结果

What Is the Implant Survivorship and Functional Outcome After Total Humeral Replacement in Patients with Primary Bone Tumors?
PubMed 文献 · Clin Orthop Relat Res · 2021-01-01

该回顾性研究纳入31例因原发性骨肿瘤行全肱骨置换的患者,中位年龄15岁,中位随访75个月。1年无翻修假体生存率为77%,5年为74%;总体肢体生存率1年和5年均为93%。关节外肩部切除患者5年无翻修生存率较低(50% vs 89%),功能结果MSTS中位87%、ASES中位83分。

要点

  • 全肱骨置换后早期翻修风险高,但假体存活超过1年后进一步翻修风险低。
  • 关节外肩部切除与翻修风险增加相关(5年无翻修生存率50% vs 89%)。
  • 存活患者功能结果良好,MSTS中位87%、ASES中位83分。

核心结论

  • 全肱骨置换术后功能结果良好,但早期假体翻修概率高,尤其关节外切除患者。

研究设计与样本

  • 回顾性分析1999年8月至2018年12月单中心31例全肱骨置换患者,中位年龄15岁,中位随访75个月。

主要发现

  • 1年无翻修假体生存率77%(95%CI 58%-89%),5年74%(95%CI 55%-86%)。
  • 总体肢体生存率1年和5年均为93%(95%CI 75%-98%)。
  • 关节外肩部切除5年无翻修生存率50%(95%CI 21%-74%),低于关节内切除的89%(95%CI 64%-97%),亚风险比4.4(95%CI 1.2-16.5),p=0.03。
  • 术后放疗者5年无翻修生存率40%(95%CI 5%-75%),未放疗者81%(95%CI 60%-92%),p=0.09。
  • 存活患者MSTS中位87%(IQR 67%-92%),ASES中位83分(IQR 63-89)。

关键数值与推荐

  • 全肱骨置换适用于局部晚期肉瘤、病理性骨折、跳跃转移或既往病灶内污染手术导致骨量不足的患者。

临床怎么用

  • 全肱骨置换可用于无其他稳定固定条件的肱骨肿瘤切除重建,但需告知早期翻修风险,关节外切除者尤甚。

局限性

  • 回顾性设计,样本量小(31例),功能评分仅9例存活患者可用,放疗影响因样本量小无法确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Total humeral replacement is an option to reconstruct massive bone defects after resection of locally advanced bone tumors of the humerus. However, implant survivorship, potential risk factors for implant revision surgery, and functional results of total humeral replacement are poorly elucidated because of the rarity of the procedure. QUESTIONS/PURPOSES: We asked: (1) What is the revision-free implant and overall limb survivorship after total humerus replacement? (2) What factors are associated with implant revision surgery? (3) What is the functional outcome of the procedure as determined by the Musculoskeletal Tumor Society (MSTS) score and the American Shoulder and Elbow Surgeons (ASES) score? METHODS: Between August 1999 and December 2018, 666 patients underwent megaprosthetic reconstruction after resection of a primary malignant or locally aggressive/rarely metastasizing tumor of the long bones at our department. In all, 23% (154) of these patients had a primary tumor located in the humerus. During the study, we performed total humeral replacement in all patients with a locally advanced sarcoma, in patients with pathological fractures, in patients with skip metastases, or in patients with previous intralesional contaminating surgery, who would have no sufficient bone stock for a stable implant fixation for a single joint megaprosthetic replacement of the proximal or distal humerus. We performed no biological reconstructions or reconstructions with allograft-prosthetic composites. As a result, 5% (33 of 666) of patients underwent total humerus replacement. Six percent (2 of 33) of patients were excluded because they received a custom-made, three-dimensionally (3-D) printed hemiprosthesis, leaving 5% (31) of the initial 666 patients for inclusion in our retrospective analysis. Of these, 6% (2 of 31) had surgery more than 5 years ago, but they had not been seen in the last 5 years. Median (interquartile range) age at the time of surgery was 15 years (14 to 25 years), and indications for total humeral replacement were primary malignant bone tumors (n = 30) and a recurring, rarely metastasizing bone tumor (n = 1). All megaprosthetic reconstructions were performed with a single modular system. The implanted prostheses were silver-coated beginning in 2006, and beginning in 2010, a reverse proximal humerus component was used when appropriate. We analyzed endoprosthetic complications descriptively and assessed the functional outcome of all surviving patients who did not undergo secondary amputation using the 1993 MSTS score and the ASES score. The median (IQR) follow-up in all survivors was 75 months (50 to 122 months), with a minimum follow-up period of 25 months. We evaluated the following factors for possible association with implant revision surgery: age, BMI, reconstruction length, duration of surgery, extraarticular resection, pathological fracture, previous intralesional surgery, (neo-)adjuvant radio- and chemotherapy, and metastatic disease. RESULTS: The revision-free implant survivorship at 1 year was 77% (95% confidence interval 58% to 89%) and 74% (95% CI 55% to 86%) at 5 years. The overall limb survivorship was 93% (95% CI 75% to 98%) after 1 and after 5 years. We found revision-free survivorship to be lower in patients with extraarticular shoulder resection compared with intraarticular resections (50% [95% CI 21% to 74%] versus 89% [95% CI 64% to 97%]) after 5 years (subhazard ratios for extraarticular resections 4.4 [95% CI 1.2 to 16.5]; p = 0.03). With the number of patients available for our analysis, we could not detect a difference in revision-free survivorship at 5 years between patients who underwent postoperative radiotherapy (40% [95% CI 5% to 75%]) and patients who did not (81% [95% CI 60% to 92%]; p = 0.09). The median (IQR) MSTS score in 9 of 13 surviving patients after a median follow-up of 75 months (51 to 148 months) was 87% (67% to 92%), and the median ASES score was 83 (63 to 89) of 100 points, with higher scores representing better function. CONCLUSION: Total humeral replacement after resection of locally advanced bone tumors appears to be associated with a good functional outcome in patients who do not die of their tumors, which in our study was approximately one- third of those who were treated with a resection and total humerus prosthesis. However, the probability of early prosthetic revision surgery is high, especially in patients undergoing extraarticular resections, who should be counseled accordingly. Still, our results suggest that if the prosthesis survives the first year, further risk for revision appears to be low. Future studies should reexamine the effect of postoperative radiotherapy on implant survival in a larger cohort and evaluate whether the use of soft tissue coverage with plastic reconstructive surgery might decrease the risk of early revisions, especially in patients undergoing extraarticular resections. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Schneider KN, Bröking JN, Gosheger G, et al. What Is the Implant Survivorship and Functional Outcome After Total Humeral Replacement in Patients with Primary Bone Tumors? Clin Orthop Relat Res. 2021. PMID: 33595237. doi:10.1097/CORR.0000000000001677

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。